I had a very nice conversation with the author of the Evolution Capital report. She told me that she did get the FDA timeline from the company. I am still very skeptical that an approval can happen before 2026 given my experience as a US biotech investor but that's how Wayne and crew see it and I'd obviously love to be proven wrong. She also stressed that there is a LOT going on behind the scenes, which I haven't doubted but was good to hear.
She also told me that there is a wall between Evolution Capital's research arm, where she works, and their investment services, so this report being released by the same company that has served as a placement agent for Anteris' offerings in the past doesn't mean anything with respect to a future raise.
Also, I want to stress that she has no inside info about this but she has a very strong gut feeling that a buyout is inevitable. Like really strong.
I had a very nice conversation with the author of the Evolution...
-
- There are more pages in this discussion • 93 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.15 |
Change
0.350(2.97%) |
Mkt cap ! $256.8M | |||
| Open | High | Low | Value | Volume |
| $11.80 | $12.15 | $11.21 | $376.0K | 32.22K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 139 | $12.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.15 | 830 | 1 |
View Market Depth
| Last trade - 16.10pm 04/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |